石四药集团(02005):非洛地平已获国家药监局批准登记成为在上市制剂使用的原料药

智通财经
Apr 10

智通财经APP讯,石四药集团(02005)发布公告,本集团的非洛地平已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。

非洛地平主要用于治疗轻、中度原发性高血压,以及稳定型心绞痛。诚如本公司日期为2023年3月30日的公告所载,本集团的非洛地平/非洛地平 II 缓释控释片(5mg)已在中国全国药品集中采购中标。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10